Ganaxolone (CCD-1042; C-1042; Ztalmy) is a novel, CNS-active and potent GABAA modulator. As of March 2022, the US FDA has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. This is the first treatment for seizures associated with CDD and the first treatment specifically for CDD. Ganaxolone acts on well-characterized targets in the brain known to have anxiolytic and anticonvulsant effects.

纯度：≥98%

CAS：38398-32-2